In patients with low-risk group, a higher proportions infiltrating of resting CD4 memory T cells, activated CD8 T cells, effector memory CD8 T cell, central memory CD4 T cell, type 1 helper T cell, activated B cell and resting mast cells were found, and which contribute to the anti-tumor immunity and are positively associated with prognosis (Chamoto et al., 2006; Lange et al., 2019; Han et al., 2020; Xu et al., 2020). This evidence concerns the gene CD4 and neoplasm.